Atsena Therapeutics News and Activities

Acquisition, funding and merger involving Atsena Therapeutics.

• Atsena Therapeutics has just announced a $150 Million fundraising (posted on April 4 2025).

View the org chart displaying its 11 main executives

Most searched biographies at Atsena Therapeutics

• Patrick Ritschel, Chief Executive Officer
• Christina Isacson, Director
• Jackie Grant, Director

Create your alert
to follow the executive moves at Atsena Therapeutics.

Atsena Therapeutics has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).
• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (posted on April 30 2025)..

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Atsena Therapeutics

• Cams Live: Shows XXX et Chat Porno Live - BongaCams
• News, Annonces et Concours BongaCams
• Atsena Therapeutics – Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
• Atsena Therapeutics – Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
• Atsena Therapeutics – Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
• Atsena Therapeutics – Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
• Atsena Therapeutics – Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting
• Atsena Therapeutics – Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
• Atsena Therapeutics – Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting
• Atsena Therapeutics – Atsena Therapeutics Appoints Linda B. Couto, PhD, as Chief Scientific Officer
• View more press releases Close

Social media about Atsena Therapeutics

• Atsena Therapeutics on Wikipedia, Google News & Yahoo Finance
• Atsena Therapeutics on LinkedIn, Twitter & YouTube